News

Special Report by: Dr. Johana Fajardo, DNP, ANP-BC CHFN FHFSA Infiltrative Cardiomyopathy Director, MedStar Washington Hospital Center; Chair of ARC Amyloidosis Nurse Collaborative   The XVIII International Symposium on Amyloidosis (ISA) took place September 4-8, 2022 in Heidelberg, Germany. The...

  Today the Amyloidosis Research Consortium (ARC), a patient-led research organization for amyloidosis diseases, announces the launch of ASPIRE: Amyloidosis Stakeholder Partnerships for Impact Reach and Equity, a collaborative of biotech and pharmaceutical companies committed to advancing solutions, improving diagnosis...

The American Association of Heart Failure Nurses (AAHFN) hosted its 18th annual meeting June 15-17, 2022 gathering nurses, care providers, industry sponsors, and other stakeholders for three full days of heart failure-related research, scientific, and programmatic knowledge-sharing. The ARC education...

BREAKING NEWS: The U.S. Food and Drug Administration today approved Alnylam Pharmaceuticals AMVUTTRATM, a novel therapy for the treatment of hereditary transthyretin (hATTR) amyloidosis with polyneuropathy. This approval comes after positive results from the readout of HELIOS-A Phase III study...

The Amyloidosis Forum, a public-private partnership initiated between the Amyloidosis Research Consortium and FDA, was highlighted recently during FDA Rare Disease Day Virtual Public Meeting on March 4th as an exemplary model to enhance product development using a public-private partnership...